Implantable Scaffold Manufactures CAR-T Cells Inside the Body Against Cancer

CAR-T cell therapy has transformed the treatment of certain blood cancers, but the technology carries a critical bottleneck: T cells must be extracted from a patient, genetically engineered in a specialized facility over several weeks, and reinfused — a process that costs hundreds of thousands of dollars and is unavailable to most patients worldwide. A smarter approach would skip the factory entirely and perform the reprogramming inside the body.

Researchers from the University of North Carolina at Chapel Hill and North Carolina State University designed a bioinstructive implantable scaffold — a porous biomaterial loaded with viral vectors and immune-stimulating signals — that can be placed near a tumor site. Once implanted, the scaffold recruits circulating T cells, delivers the CAR-encoding genetic payload directly to them, and then releases the newly minted CAR-T cells into the body to seek and destroy cancer cells.

The original 2022 Nature Biotechnology study demonstrated proof-of-concept in preclinical models, showing that the scaffold could generate functional CAR-T cells in vivo with antitumor activity comparable to conventionally manufactured cells. The approach bypasses the need for ex vivo expansion, leukapheresis, and clean-room manufacturing infrastructure.

The implications extend beyond cost savings. In vivo manufacturing could reduce the risk of T cell exhaustion that sometimes occurs during lengthy ex vivo culture, potentially yielding fresher, more potent cells. It also opens the door to repeat dosing via sequential scaffold implants.

This 2026 PubMed entry is an author correction to the original paper, not a new study, so no additional experimental data are reported here. The underlying science, however, represents a landmark advance in regenerative medicine and cancer immunotherapy with significant implications for making curative cell therapies broadly accessible.